title: Association of statin therapy with outcomes of acute coronary syndromes: the GRACE study.
abstract: BACKGROUND
  Statins administered early in patients with acute coronary syndromes may lead to modest reductions in recurrent ischemic events.
  
  
  OBJECTIVE
  To examine the association between previous and early in-hospital statin therapy and the presentation and outcomes of an acute coronary syndrome.
  
  
  METHODS
  Cohort study.
  
  
  METHODS
  94 hospitals in 14 countries participating in the Global Registry of Acute Coronary Events (GRACE).
  
  
  METHODS
  19,537 patients with an acute coronary syndrome who were enrolled from April 1999 to September 2002.
  
  
  METHODS
  Statin use before and after presentation with an acute coronary syndrome and associated rates of myocardial infarction, hospital complications, and hospital mortality. The composite end point included death, in-hospital myocardial infarction, and stroke.
  
  
  RESULTS
  Patients who were already taking statins when they presented to the hospital were less likely to have ST-segment elevation (odds ratio [OR], 0.79 [95% CI, 0.71 to 0.88]) or myocardial infarction (OR, 0.78 [CI, 0.70 to 0.86]). Patients who continued to take statins in the hospital were less likely to experience complications or die than patients who never received statins (OR, 0.66 [CI, 0.56 to 0.77]). Patients not previously taking statins who began statin therapy in the hospital were less likely to die than patients who never received statin therapy (OR, 0.38 [CI, 0.30 to 0.48]). However, adjustment for the hospital of admission attenuated the association between initiation of statin therapy and the composite end point (OR, 0.84 [CI, 0.65 to 1.10]).
  
  
  CONCLUSIONS
  This observational study cannot exclude confounding by clinical and hospital factors.
  
  
  CONCLUSIONS
  These data support the hypothesis that statin therapy can modulate early pathophysiologic processes in patients with acute coronary syndromes. A randomized trial of statin therapy in acute myocardial infarction is warranted.
authors.affiliation: Department of Medicine/Division of Cardiovascular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts 01655, USA. spencerf@ummhc.org
authors.forename: Frederick A
authors.initials: FA
authors.lastname: Spencer
authors.forename: Jeanna
authors.initials: J
authors.lastname: Allegrone
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Goldberg
authors.forename: Joel M
authors.initials: JM
authors.lastname: Gore
authors.forename: Keith A A
authors.initials: KA
authors.lastname: Fox
authors.forename: Christopher B
authors.initials: CB
authors.lastname: Granger
authors.forename: Rajendra H
authors.initials: RH
authors.lastname: Mehta
authors.forename: David
authors.initials: D
authors.lastname: Brieger
mesh_terms: D000367:Age Factors; D000368:Aged; D015331:Cohort Studies; D003327:Coronary Disease / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D004562:Electrocardiography; D005260:Female; D017052:Hospital Mortality; D006760:Hospitalization; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000209:etiology / Q000517:prevention & control; D055502:Secondary Prevention; D020521:Stroke / Q000209:etiology / Q000517:prevention & control; D013577:Syndrome; D016896:Treatment Outcome
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors